澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

CLARITY PHARMACEUTICALS LTD

1.920

+0.0754.07%

成交量：239.68万

成交额：457.47万

市值：7.14亿

市盈率：-6.59

高：1.945

开：1.910

低：1.850

收：1.845

52周最高：5.870

52周最低：1.800

股本：3.72亿

流通股本：2.74亿

量比：1.00

换手率：0.87%

股息：- -

股息率：- -

每股收益(TTM):-0.291

每股收益(LYR):-0.291

净资产收益率：-77.54%

总资产收益率：-45.12%

市净率：3.84

市盈率(LYR):-6.59

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Clarity Pharmaceuticals关键试验数据亮眼：8 GBq剂量下，PSA25、PSA50、PSA75及PSA90应答率分别达74%、63%、53%和26%

Clarity Pharmaceuticals：8 Gbq剂量下81%疾病控制率，31%完全缓解/疾病不可检测

Clarity Pharmaceuticals与Nucleus Radiopharma签署Cu-64 SAR-Bispsma商业化生产协议

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/CU6.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":1.92,"timestamp":1791781920000,"preClose":1.845,"halted":0,"volume":2396814,"delay":0,"changeRate":0.04065040650406502,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.291397,"marketStatus":"未开盘","change":0.075,"latestTime":"10-12 16:12:00 AEDT","open":1.91,"high":1.945,"low":1.85,"amount":4574726,"amplitude":0.051491,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.291397,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791846000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":1.845,"openAndCloseTimeList":[[1791759600000,1791781200000]],"volumeRatio":0.9979406767705055,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CU6.AU","preClose":1.845,"auctionPrice":1.92,"auctionVolume":103662,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781816601}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-45.12%","roe":"-77.54%","lyrEps":-0.291397,"volumeRatio":0.9979406767705055,"shares":372030071,"dividePrice":0,"high":1.945,"amplitude":0.051491,"preClose":1.845,"low":1.85,"week52Low":1.8,"pbRate":"3.84","psRate":"67.86","week52High":5.87,"institutionHeld":0,"latestPrice":1.92,"eps":-0.291397,"divideRate":0,"volume":2396814,"delay":0,"ttmEps":-0.291397,"open":1.91,"prevYearClose":3.38,"prevWeekClose":1.845,"prevMonthClose":2.1,"prevQuarterClose":2.1,"fiveDayClose":2.09,"twentyDayClose":2.14,"sixtyDayClose":2.32,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1187278949","title":"Clarity Pharmaceuticals关键试验数据亮眼：8 GBq剂量下，PSA25、PSA50、PSA75及PSA90应答率分别达74%、63%、53%和26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187278949","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187278949?lang=zh_cn&edition=fundamental","pubTime":"2026-08-05 21:10","pubTimestamp":1785935406,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals在SECuRE试验中取得重大进展——在8 GBq剂量方案下，患者PSA25应答率高达74%，PSA50为63%，PSA75达到53%，而PSA90应答率也录得26%的亮眼表现。这一数据展现出该药物在前列腺癌治疗领域令人瞩目的潜力，为后续临床开发与商业化铺就了坚实基石。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175170356","title":"Clarity Pharmaceuticals：8 Gbq剂量下81%疾病控制率，31%完全缓解/疾病不可检测","url":"https://stock-news.laohu8.com/highlight/detail?id=1175170356","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175170356?lang=zh_cn&edition=fundamental","pubTime":"2026-08-05 21:06","pubTimestamp":1785935169,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals的研究数据显示，在8 Gbq剂量下，患者疾病控制率高达81%。更令人振奋的是，完全缓解或疾病达到不可检测状态的比例达到了31%。这一结果无疑为该公司在癌症治疗领域的探索注入了强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145830308","title":"Clarity Pharmaceuticals与Nucleus Radiopharma签署Cu-64 SAR-Bispsma商业化生产协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1145830308","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145830308?lang=zh_cn&edition=fundamental","pubTime":"2026-04-14 06:35","pubTimestamp":1776119715,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd近日宣布，已与Nucleus Radiopharma达成一项重要合作，双方正式签署了关于放射性药物Cu-64 SAR-Bispsma的商业化生产协议。该协议的签署标志着Clarity在核医学领域的产业化进程迈出关键一步，为其前列腺癌靶向诊疗产品的规模化供应奠定基础。通过此次合作，Nucleus Radiopharma将依托其符合药品生产质量管理规范的生产设施，为Clarity提供符合临床级标准的Cu-64 SAR-Bispsma放射性药物。Cu-64 SAR-Bispsma作为一种新型靶向放射诊疗药物，可通过PET成像技术精准定位前列腺癌病灶，同时具备治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CU6.AU\",params:#limit:6,delay:true,,,undefined,":[]}}